The Inspirational Quest to Eradicate Cancer

The world-renowned Thoracic Oncologist, Dr. Gerold Bepler, joined I Don’t Care’s Kevin Stevenson for a conversation that was no less than inspirational. Dr. Bepler, President and CEO of the Karmanos Cancer Institute, has a mission; to eradicate cancer. It’s more than a dream for Dr. Bepler; he believes it will be a reality one day.

Dr. Bepler arrived from Germany to the United States in 1983. Following a post-doctoral fellowship at the National Cancer Institute, the starting point for his journey into lung cancer research. This career path took Dr. Bepler through many stops along the way, and in 2010 he joined the Karmanos Cancer Institute.

The mission to eradicate cancer got a boost in 1971 with the National Cancer Act, and Dr. Bepler said there’s tremendous progress towards this goal since that point. “People now diagnosed with cancer have hope,” Dr. Bepler said. “And many of them get cured of the disease and have a good quality of life. That all wouldn’t have been possible without the National Cancer Act.”

Much of the progress made to eradicating cancer at the Karmanos Cancer Institute owes a debt of gratitude to that 50-year-old law for providing necessary funding that makes such research possible.

“The Karmanos Cancer Institute became one of the NCI designated cancer centers,” Dr. Bepler said. “Very quickly, the National Cancer Institute realized just having one cancer institute in Bethesda, Maryland alone wouldn’t be able to achieve that high goal of eradicating cancer. This network established cancer centers throughout the United States.” What started as a couple of centers in the 1970s is now more than 50 comprehensive cancer centers.

The world now possesses many drugs and treatments to treat cancer through the dedication and research of institutes like the Karmanos Center. And some research led to treatments for other diseases. Dr. Bepler mentioned the Karmanos Center developed three of the first FDA-approved AIDS drugs.

More Like This Story:

The Rising Tide of Food Allergens

From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs

Follow us on social media for the latest updates in B2B!

Image

Latest

AI adoption strategy
Five by Five Leadership: Why Purpose, Warmth, and Clarity Matter More Than Ever at Work
February 10, 2026

For the first time in history, workplaces now span five generations, forcing leaders to rethink long-standing assumptions about motivation, communication, and career growth. As Gen Z enters the workforce, they bring expectations shaped by a desire for meaningful work, clear development paths, and work-life balance—rather than traditional, one-size-fits-all career ladders. In an era marked…

Read More
Experiential
Scaling Experiential Learning at Slippery Rock University with Dr. John Rindy
February 9, 2026

Regional public universities are being asked to do more with fewer students, fewer dollars, and less margin for error—making student persistence, timely graduation, and career outcomes central institutional concerns. Under mounting enrollment pressure and a shifting labor market, experiential learning has moved from a “nice to have” to a strategic imperative. Research consistently shows…

Read More
data center workforce
The Next Data Center Bottleneck Isn’t Power or Cooling — It’s People: The Data Center Workforce
February 8, 2026

With the rapid rise of AI workloads, data centers are being built with higher power density, stricter reliability expectations, and cooling technologies that are evolving faster than most teams can adapt. As a result, these facilities aren’t just getting bigger—they’re becoming harder to operate, harder to staff, and far less forgiving when something goes…

Read More
Telecom
Precision With Purpose: The Geospatial Advantage in Telecom Network Planning
February 7, 2026

Telecom networks are no longer planned or evaluated in isolation. As 5G, private LTE, fixed wireless, and mission-critical communications expand, operators are expected to deliver stronger coverage, higher reliability, and demonstrable performance—often while managing complex technologies and constrained resources. Regulators, customers, and public agencies are increasingly focused on outcomes that can be measured and…

Read More